Antibodies

17 April 2024

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

17 April 2024

Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS

16 April 2024

Mabwell Releases Preclinical Study Results of Multiple Innovative Drugs Released at the 2024 AACR Annual Meeting

16 April 2024

Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials

16 April 2024

Imfinzi plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial

16 April 2024

Pre-clinical result of LP-005, a novel bi-functional complement antibody-fusion protein was unveiled by LongBio at WCN2024

16 April 2024

Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S.

16 April 2024

SpikImm Announces the Signature of an Exclusive License Option and Collaboration Agreement With SATT Conectus for the Development of a Prophylactic Treatment Against the BK Virus, Causing Severe Complications in Transplant Patients

15 April 2024

Walden Biosciences Announces Positive Topline Data from Phase 1+ Clinical Study of WAL0921 in Development for Treatment of Kidney Diseases

15 April 2024

Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

15 April 2024

Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study

12 April 2024

Seismic Therapeutic Presents Preclinical Data on S-1117, its Novel Pan-IgG Protease Addressing Multiple Pathogenic Mechanisms in Autoimmune Disease, at American Academy of Neurology (AAN) 2024

12 April 2024

SparX Group Announces First Patient Dosed with SPX-303 Injection, the First in Its Class of anti-LILRB2/PD-L1 Bispecific Antibody Drugs

11 April 2024

Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy

11 April 2024

Macomics Unveils its Lead First-in-Class Anti-Pan-LILRB Monoclonal Antibody Programme with Positive Pre-clinical Data Presented at AACR 2024

11 April 2024

Tallac Therapeutics Presents New Preclinical Data on TAC-001 in Combination with Cancer Vaccines at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

11 April 2024

Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

10 April 2024

ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)

10 April 2024

Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024

10 April 2024

Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

10 April 2024

TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline

10 April 2024

Gennao Bio Debuts Preclinical Data for First-in-Class Antibody-Drug Conjugate from Gene Monoclonal Antibody Platform (GMAB ADC)

10 April 2024

Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

9 April 2024

Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism

9 April 2024

Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024

9 April 2024

Transcenta Announces Collaboration with Agilent to Develop a Claudin18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial

9 April 2024

BioCity Announces FDA Clearance of the Investigational New Drug Application for its First-In-Class Antibody Drug Conjugate Targeting Glypican 3

9 April 2024

Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC Candidates TUB-030 and TUB-040 Demonstrating Superior Efficacy Profile and a Wide Therapeutic Window at the AACR Annual Meeting 2024

8 April 2024

Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting

8 April 2024

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

CCR8-Targeted Antibody Immunotherapy Pipeline Review

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis

Mesothelin-Targeted Immunotherapy Pipeline Review

PD-1 Agonists Pipeline Review

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

PSMA-Targeted Therapy Pipeline Review

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

Ranibizumab (Lucentis) Biosimilars Pipeline Review